| Region | Status (as of 2026) | |--------|-------------------| | | Not scheduled at the federal level, but many states have enacted “synthetic cannabinoid” analog statutes that may cover JUQ‑103. The DEA can place it under emergency scheduling if deemed a public health threat. | | European Union | Listed in several EU Early Warning System (EWS) alerts; many member states treat it as a controlled substance under their national analogue laws. | | United Kingdom | Classified as a Class B substance under the Psychoactive Substances Act (PSA) – production, supply, or importation without a license is illegal. | | Canada | Controlled under Schedule II of the Controlled Drugs and Substances Act (as a “synthetic cannabinoid analogue”). | | Australia | Schedule 9 (Prohibited Substance) in most jurisdictions. | | Japan, Singapore, Saudi Arabia | Explicitly prohibited under national drug control legislation. |
While appears to be a specific identifier or product code, there is no widely documented or mainstream public information available regarding its origin, manufacturer, or purpose as of May 2026. JUQ-103
| Property | Detail | |----------|--------| | | Cannabinoid receptors CB₁ (central nervous system) and CB₂ (peripheral immune tissues) | | Binding affinity | Reported in vitro Ki values are in the low‑nanomolar range (≈ 2–10 nM for CB₁; ≈ 5–15 nM for CB₂) – comparable to many first‑generation synthetic cannabinoids | | Functional activity | Full agonist at both CB₁ and CB₂ (produces maximal receptor activation) | | Typical effects (human) | Euphoria, sedation, altered perception, tachycardia, appetite changes; at higher doses can cause anxiety, paranoia, vomiting, seizures | | Metabolism | Predominantly hepatic via CYP3A4 and CYP2C9; major metabolites include hydroxylated and carboxylated species that may retain activity | | Duration of action | Oral/insufflated routes: 2–6 h of noticeable psychoactive effect; metabolites can be detectable in urine for 24–48 h | | Region | Status (as of 2026) |
| Risk Factor | Probability | Impact | Mitigation Strategy | | :--- | :--- | :--- | :--- | | | Low | Critical | Maintain "Hot Standby" server running JUQ-102 until JUQ-103 is verified. | | API Incompatibility | Medium | Moderate | Ensure third-party vendors are notified of SHA-3 token structure changes. | | Data Corruption | Very Low | Critical | Full database snapshot backup mandatory prior to execution. | | | United Kingdom | Classified as a
If you are looking for specific details regarding this release, such as the , participating performers , or studio name , you can typically find them by: